[Pharmacological study on kefir--a fermented milk product in Caucasus. I. On antitumor activity (1)].
The antitumor activity of kefir (YK-1), a fermented milk product in Caucasus, was investigated. YK-1 at oral doses of 100 or 500 mg/kg inhibited the proliferation of solid tumor of Ehrlich ascites carcinoma transplanted subcutaneously in mice. YK-1 did not show an inhibitory effect on the ear swelling induced contact dermatitis caused by picryl chloride (PC-CD). However, YK-1 inhibited the immunosuppression in Ehrlich carcinoma-bearing mice and with the frozen and dried ascites of the tumor-bearing mice containing immunosuppressive substances (EC-sup) in PC-CD-induced mice. And also, YK-1 activated the immunosuppressive activity of spleen cells of mouse treated with EC-sup. These results suggest that YK-1 may have antitumor activity against Ehrlich carcinoma and activate the immunosuppression with it.
Kubo
M
M
Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.
Odani
T
T
Nakamura
S
S
Tokumaru
S
S
Matsuda
H
H
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D003611:Dairy Products; D005285:Fermentation; D007108:Immune Tolerance / Q000187:drug effects; D051379:Mice; D016685:Mitomycin / Q000008:administration & dosage / Q000494:pharmacology
D000970:Antineoplastic Agents; D016685:Mitomycin